ArticleInternational journal of nanomedicine2025
Chitosan Nanoparticles for Pulmonary Delivery of Curcumin/Nintedanib to Treat Pulmonary Fibrosis.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Enhancing anti-fibrotic therapy: nanomedicine approaches to overcome current limitations.Materials today. Bio · 2026Review
- Antifibrotic mechanism of curcumin and its therapeutic potential in multi-organ diseases.Frontiers in pharmacology · 2026Review
- Lung-Targeted Lipid Nanoparticles Delivery of Wogonin for Pulmonary Fibrosis in Mice via Modulation of Cellular Proteostasis.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Pulmonary fibrosis is a chronic, progressive lung disease with a high mortality rate. Currently, the treatment options for IPF involve the oral administration of nintedanib (NDNB); however, these therapies are hampered by low oral bioavailability. This study aimed to develop chitosan-based nanoparticles for pulmonary delivery to enhance the therapeutic effects of curcumin (Cur) and NDNB. Methods: We successfully prepared and optimized Cur-loaded chitosan nanoparticles (Cur/CS-VES NPs) and NDNB-loaded chitosan nanoparticles (NDNB/CS-PGA NPs) through a standardized process. In vitro, Calu-3 and HFL1 cells were treated to evaluate the biocompatibility of chitosan nanocarrier materials and the antifibrotic activity of drug-loaded nanoparticles, respectively. In vivo, the bleomycin-induced rat models of pulmonary fibrosis were established to study the efficacy of chitosan nanoparticles. Results: In vitro experiments indicated that the drug-loaded chitosan nanoparticles exhibited good stability and low cytotoxicity. In vivo pharmacodynamic studies revealed that, compared with oral administration of Cur or NDNB alone, the pulmonary delivery of Cur/CS-VES NPs and NDNB/CS-PGA NPs effectively inhibited the progression of pulmonary fibrosis, improved lung function, reduced levels of inflammatory factors, and mitigated pathological lesions in the lungs. These findings suggest that chitosan-based nano-particles have promising potential as pulmonary inhalation agents for the treatment of pulmonary fibrosis. Conclusion: These findings highlight the great potential of chitosan-based nanoparticles as a therapeutic strategy for treating IPF and related pulmonary fibrosis with pulmonary delivery pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.